Therapeutic potential and mechanism of action of oligonucleotides and ribozymes

Biochemical and Molecular Medicine

Volumn 62, Issue 1, 1997, Pages 11-22

  Lavrovsky, Yan ^a   Chen, Shuo ^a   Roy, Arun K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; RIBOZYME;

BASE PAIRING; COVALENT BOND; DEGENERATIVE DISEASE; DNA SEQUENCE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENZYME DEGRADATION; GENE EXPRESSION REGULATION; NONHUMAN; PROMOTER REGION; REVIEW; TRIPLE HELIX;

EID: 0031259504     PISSN: 10773150     EISSN: None     Source Type: Journal    
DOI: 10.1006/bmme.1997.2631     Document Type: Review

References (173)

1. 1. Birnboim HC, Sederoff RR, Paterson MC. Distribution of polypyrimidine · polypurine segments in DNA from diverse organisms. Eur J Biochem 98:301-307, 1979.
2. 2. Hoffman-Liebermann B, Liebermann D, Troutt A, Kedes LH, Cohen SN. Human homologs of TU transposon sequences: Polypurine/polypyrimidine sequence elements that can alter DNA confirmation in vitro and in vivo. Mol Cell Biol 6:3632-3642, 1986.
3. 3. Wells RD, Collier DA, Hanvey JC, Shimizu M, Wohlrab F. The chemistry and biology of unusual DNA structures adopted by oligopurine · oligopyrimidine sequences. FASEB J 2:2939-2949, 1988. [Review]
4. 4. Boulikas T. Nature of DNA sequences at the attachment regions of genes to the nuclear matrix. J Cell Biochem 52:14-22, 1993. [Review]
5. 5. Orson FM, Thomas DW, McShan WM, Kessler DJ, Hogan ME. Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes. Nucleic Acids Res 19:3435-3441, 1991.
6. 6. Ulrich MJ, Gray WJ, Ley TJ. An intramolecular DNA triplex is disrupted by point mutations associated with hereditary persistence of fetal hemoglobin. J Biol Chem 267:18649-18658, 1992.
7. 7. Kolluri R, Torrey TA, Kinniburgh AJ. A CT promoter element binding protein: Definition of a double-strand and a novel single-strand DNA binding motif. Nucleic Acids Res 20:111-116, 1992.
8. 8. Horwitz EM, Maloney KA, Ley TJ. A human protein containing a "cold shock" domain binds specifically to H-DNA upstream from the human gamma-globin genes. J Biol Chem 269:14130-14139, 1994.
9. 9. Lee JS, Woodsworth ML, Latimer LJ, Morgan AR. Poly (pyrimidine) · poly(purine) synthetic DNAs containing 5-methylcytosine form stable triplexes at neutral pH. Nucleic Acids Res 12:6603-6614, 1984.
10. 10. Wang G, Seidman MM, Glazer PM. Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 271:802-805, 1996.
11. 11. Burkholder GD, Latimer LJ, Lee JS. Immunofluorescent staining of mammalian nuclei and chromosomes with a monoclonal antibody to triplex DNA. Chromosoma 97:185-192, 1988.
12. 12. Burkholder GD, Latimer LJ, Lee JS. Immunofluorescent localization of triplex DNA in polytene chromosomes of Chironomus and Drosophila. Chromosoma 101:11-18, 1991.
13. 13. Thomas TJ, Seibold JR, Adams LE, Hess EV. Triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine. Biochem J 311:183-188, 1995.
14. 14. Rich A. DNA comes in many forms. Gene 135:99-109, 1993.
15. 15. Kim H-G, Miller DM. Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter. Biochemistry 34:8165-8171, 1995.
16. 16. Felsenfeld G, Davies DR, Rich A. Formation of a three-stranded polynucleotide molecule. J Am Chem Soc 79:2023-2024, 1957.
17. 17. Postel EH, Flint SJ, Kessler DJ, Hogan ME. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci USA 88:8227-8231, 1991.
18. 18. Han H, Dervan PB. Different conformational families of pyrimidine · purine · pyrimidine triple helices depending on backbone composition. Nucleic Acids Res 22:2837-2844, 1994.
19. 19. Mayfield C, Squibb M, Miller D. Inhibition of nuclear protein binding to the human Ki-ras promoter by triplex-forming oligonucleotides. Biochemistry 33:3358-3363, 1994.
20. 20. Radhakrishnan I, Patel DJ. DNA triplexes: Solution structures, hydration sites, energetics, interactions, and function. Biochemistry 33:11405-11416, 1994.
21. 21. Olivas EM, Maher LJ, III. DNA recognition by alternate strand triple helix formation: Affinities of oligonucleotides for a site in the human p53 gene. Biochemistry 33:983-991, 1994.
22. 22. Radhakrishnan I, de los Santos C, Patel DJ. Nuclear magnetic resonance structural studies of A.AT base triple alignments in intramolecular purine · purine · pyrimidine DNA triplexes in solution. J Mol Biol 234:188-197, 1993.
23. 23. Radhakrishnan I, Patel DJ. Solution structure of a purine-· purine · pyrimidine DNA triplex containing G.GC and T.AT triples. Structure 1:135-152, 1993.
24. 24. Radhakrishnan I, Patel DJ. Solution structure of a pyrimidine · purine · pyrimidine DNA triplex containing T.AT, C+.GC and G.TA triples. Structure 2:17-32, 1994.
25. 25. Lee JS, Johnson DA, Morgan AR. Complexes formed by (pyrimidine)n · (purine)n DNAs on lowering the pH are three-stranded. Nucleic Acids Res 6:3073-3091, 1979.
26. 26. Han H, Dervan PG. Different conformational families of pyrimidine · purine · pyrimidine triple helices depending on backbone composition. Nucleic Acids Res 22:2837-2844, 1994.
27. 27. Hanvey JC, Williams EM, Besterman JM. DNA triple-helix formation at physiologic pH and temperature. Antisense Res Dev 1:307-317, 1991.
28. 28. Cheng A-J, Van Dyke MW. Oligodeoxyribonucleotide length and sequence effects on intermolecular purine-purine-pyrimidine triple-helix formation. Nucleic Acids Res 22:4742-4747, 1994.
29. 29. Washbrook E, Fox KR. Comparison of antiparallel A.AT and T.AT triplets within an alternate strand DNA triple helix. Nucleic Acids Res 22:3977-3982, 1994.
30. 30. Jayasena SD, Johnston BH. Oligonucleotide-directed triple helix formation at adjacent oligopurine and oligopyrimidine DNA tracts by alternate strand recognition. Nucleic Acids Res 20:5279-5288, 1992.
31. 31. Hobbs CA, Yoon K. Differential regulation of gene expression in vivo by triple helix-forming oligonucleotides as detected by a reporter enzyme. Antisense Res Dev 4:1-8, 1994.
32. 32. Jayasena SD, Johnson BH. Sequence limitations of triple helix formation by alternate-strand recognition. Biochemistry 32:2800-2807, 1993.
33. 33. Yoon K, Hobbs CA, Koch J, Sardago M, Kutny R, Weis AL. Elucidation of the sequence-specific third-strand recognition of four Watson-Crick base pairs in a pyrimidine triple-helix motif: T.AT, C.GC, T.CG, and G.TA. Proc Natl Acad Sci USA 89:3840-3844, 1992.
34. 34. Durland RH, Rao TS, Revankar GR, Tinsley JH, Myrick MA, Seth DM, Rayford J, Singh P, Jayaraman K. Binding of T and T analogs to CG base pairs in antiparallel triplexes. Nucleic Acids Res 22:3233-3240, 1994.
35. 35. Malkov VA, Voloshin ON, Veselkov AG, Rostapshov VM, Jansen I, Soyfer VN, Frank-Kamenetskii MD. Protonated pyrimidine-purine-purine triplex. Nucleic Acids Res 21:105-111, 1993.
36. 36. Blume SW, Gee JE, Shrestha K, Miller DB. Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter. Nucleic Acids Res 20:1777-1784, 1992.
37. 37. Maher LJ. DNA triple-helix formation: An approach to artificial gene repressers? BioEssays 14:807-815, 1992.
38. 38. Spitzner JR, Chung IK, Muller MT. Determination of 5′ and 3′ DNA triplex interference boundaries reveals the core DNA binding sequence for topoisomerase II. J Biol Chem 270:5932-5943, 1995.
39. 39. Duval-Valentin G, Thuong NT, Helene C. Specific inhibition of transcription by triple helix-forming oligonucleotides. Proc Natl Acad Sci USA 89:504-508, 1992.
40. 40. Weston L, Blomquist P, Milligan JF, Wrange O. Triple helix DNA alters nucleosomal histone-DNA interactions and acts as a nucleosome barrier. Nucleic Acids Res 23:2184-2191, 1995.
41. 41. Escude C, Giovannangeli C, Sun JS, Lloyd DH, Chen JK, Gryaznov SM, Garestier T, Helene C. Stable triple helices formed by oligonucleotide N3′ → P5′ phosphoramidates inhibit transcription elongation. Proc Natl Acad Sci USA 93:4365-4369, 1996.
42. 42. Mouscadet JF, Carteau S, Goulaouic H, Subra F, Auclair C. Triplex-mediated inhibition of HIV DNA integration in vitro. J Biol Chem 269:21635-21638, 1994.
43. 43. Volkmann S, Jendis J, Frauendorf A, Moelling K. Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA. Nucleic Acids Res 23:1204-1212, 1995.
44. 44. Svinarchuk F, Monnot M, Merle A, Malvy C, Fermandjian S. The high stability of the triple helices formed between short purine oligonucleotides and SIV/HIV-2 vpx genes is determined by the targeted DNA structure. Nucleic Acids Res 23:3831-3836, 1995.
45. 45. Bouziane M, Cherny DI, Mouscadet JF, Auclair C. Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro. J Biol Chem 271:10359-10364, 1996.
46. 46. Ouali M, Bouziane M, Ketterle C, Gabarro-Arpa J, Auclair C, LeBret M. A molecular mechanics and dynamics study of alternate triple-helices involving the integrase-binding site of the HIV-1 virus and oligonucleotides having a 3′-3′ internucleotide junction. J Biomol Struct Dyn 13:835-853, 1996.
47. 47. Mayfield C, Squibb M, Miller D. Inhibition of nuclear protein binding to the human Ki-ras promoter by triplex-forming oligonucleotides. Biochemistry 33:3358-3363, 1994.
48. 48. Reddoch JF, Miller DM. Inhibition of nuclear protein binding to two sites in the murine c-myc promoter by intermolecular triplex formation. Biochemistry 34:7659-7667, 1995.
49. 49. Kim H-G, Miller DM. Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter. Biochemistry 34:8165-8171, 1995.
50. 50. Thomas TJ, Faaland CA, Gallo MA, Thomas T. Suppression of c-myc oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 breast cancer cells. Nucleic Acids Res 23:3594-3599, 1995.
51. 51. Olivas WM, Maher LJ III. DNA recognition of alternate strand triple helix formation: Affinities of oligonucleotides for a site in the human p53 gene. Biochemistry 33:983-991, 1994.
52. 52. Svinarchuk F, Debin A, Bertrand JR, Malvy C. Investigation of the intracellular stability and formation of a triple helix formed with a short purine oligonucleotide targeted to the murine c-pim-1 proto-oncogene promoter. Nucleic Acids Res 24:295-302, 1996.
53. 53. Song CS, Jung MH, Supakar PC, Chen S, Vellanoweth RL, Chatterjee B, Roy AK. Regulation of androgen action by receptor gene inhibition. Ann NY Acad Sci 761:97-108, 1995.
54. 54. Ing NH, Beekman JM, Kessler DJ, Murphy M, Jayaraman K, Zendegui JG, Hogan ME, O'Malley BW, Tsai MJ. In vivo transcription of a progesterone-responsive gene is specifically inhibited by a triplex-forming oligonucleotide. Nucleic Acids Res 21:2789-2796, 1993.
55. 55. Takasugi M, Guendouz A, Chassignol M, Decout JL, L'homme J, Thuong NT, Helene C. Sequence-specific photo-induced cross-linking of the two strands of double-helical DNA by a psoralen covalently linked to a triple helix forming oligonucleotide. Proc Natl Acad Sci USA 88:5602-5606, 1991.
56. 56. Giovannangeli C, Thuong NT, Helene C. Oligodeoxynucleotide-directed photo-induced cross-linking of HIV proviral DNA via triple-helix formation. Nucleic Acids Res 20:4275-4281, 1992.
57. 57. Gasparro FP, Havre PA, Olack GA, Gunther EJ, Glazer PM. Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: Characterization of psoralen monoadduct and crosslink formation. Nucleic Acids Res 22:2845-2852, 1994.
58. 58. Sunters A, Springer CJ, Bagshawe KD, Souhami RL, Hartley JA. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol 44:59-64, 1992.
59. 59. Giovannangeli C, Rougee M, Garestier T, Thuong NG, Helene C. Triple-helix formation by oligonucleotides containing the three bases thymine, cytosine, and guanine. Proc Natl Acad Sci USA 89:8631-8635, 1992.
60. 60. Perrouault L, Asseline U, Rivalle C, Thuong NT, Bisagni E, Giovannangeli C, LeDoan T, Helene C. Sequence-specific artificial photo-induced endonucleases based on triple helix-forming oligonucleotides. Nature 344:358-360, 1990.
61. 61. Brossalina EB, Demchenko EN, Vlassov VV, Mamaev SV. Sequence-specific alkylation of dsDNA with derivatives of pyrimidine oligonucleotides conjugated to 2-chloroethylamine groups. Antisense Res Dev 1:229-242, 1991.
62. 62. Brossalina EB, Demchenko EN, Vlassov VV. Specificity of interaction of pyrimidine oligonucleotides with DNA at acidic pH in the presence of magnesium ions: Affinity modification study. Antisense Res Dev 3:357-365, 1993.
63. 63. Wang G, Levy DD, Seidman MM, Glazer PM. Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol Cell Biol 15:1759-1768, 1995.
64. 64. Gunther EJ, Havre PA, Gasparro FP, Glazer PM. Triplex-mediated, in vitro targeting of psoralen photoadducts within the genome of a transgenic mouse. Photochem Photobiol 63:207-212, 1996.
65. 65. Lavrovsky Y, Stoltz RA, Vlassov VV, Abraham NG. C-fos protooncogene transcription can be modulated by oligonucleotide-mediated formation of triplex structures in vitro. Eur J Biochem 238:582-590, 1996.
66. 66. Brown JR, Ye H, Bronson RT, Dikkes P, Greenberg ME. A defect in nurturing in mice lacking the immediate early gene fosB. Cell 86:297-309, 1996.
67. 67. Bialy M, Kaczmarek L. c-Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Acta Neurobiol Exp 56:567-577, 1996.
68. 68. Muller R, Mumberg D, Lucibello FC. Signals and genes in the control of cell-cycle progression. Biochim Biophys Acta 1155:151-179, 1993.
69. 69. Lavrovsky YV, Svinarchuk FP, Lavrovsky VA, Yefremov YR, Vlassov VV. c-fos-gene expression in cell revertants from a transformed to a pseudonormal phenotype. FEBS Lett 316:161-164, 1993.
70. 70. Curran T, Morgan JI. Fos: An immediate-early transcription factor in neurons. J Neurobiol 26:403-412, 1995.
71. 71. Lavrovsky Y, Mastyugin V, Stoltz RA, Abraham NG. Specific inhibition of c-fos proto-oncogene expression by triple-helix-forming oligonucleotides. J Cell Biochem 61:301-309, 1996.
72. 72. Fox KR, Polucci P, Jenkins TC, Neidle S. A molecular anchor for stabilizing triple-helical DNA. Proc Natl Acad Sci USA 92:7887-7891, 1995.
73. 73. Mergny JL, Duval-Valentin G, Nguyen CH, Perrouault L, Faucon B, Rougee M, Montenay-Garestier T, Bisagni E, Helene C. Triple helix-specific ligands. Science 256:1681-1684, 1992.
74. 74. Pilch DS, Waring MJ, Sun JS, Rougee M, Nguyen CH, Bisagni E, Garestier T, Helene C. Characterization of a triple helix-specific ligand. BePI (3-methoxy-7H-8-methyl-II-[(3′-amino)propylamino]-benzo[e]pyrido[4,3-b]indole) intercalates into both double-helical and triple-helical DNA. J Mol Biol 232:926-946, 1993.
75. 75. Lee JS, Latimer LJ, Hampel KJ. Coralyne binds tightly to both T.A.T-and C.G.C(+)-containing DNA triplexes. Biochemistry 32:5591-5597, 1993.
76. 76. Wilson WD, Tanious FA, Mizan S, Yao S, Kiselyov AS, Zon G, Strekowski L. DNA triple-helix specific intercalators as antigene enhancers: Unfused aromatic cations. Biochemistry 32:10614-10621, 1993.
77. 77. Chandler SP, Strekowski L, Wilson WD, Fox KR. Foot-printing studies on ligands which stabilize DNA triplexes: Effects on stringency within a parallel triple helix. Biochemistry 34:7234-7242, 1995.
78. 78. Cassidy SA, Strekowski L, Wilson WD, Fox KR. Effect of a triplex-binding ligand on parallel and antiparallel DNA triple helices using short unmodified and acridine-linked oligonucleotides. Biochemistry 33:15338-15347, 1994.
79. 79. Fox KR, Thurston DE, Jenkins TC, Varvaresou A, Tsotinis A, Siatra-Papastaikoudi T. A novel series of DNA triple helix-binding ligands. Biochem Biophys Res Commun 224:717-720, 1996.
80. 80. Semerad CL, Maher LJ. Exclusion of RNA strands from a purine motif triple helix. Nucleic Acids Res 22:5321-5325, 1994.
81. 81. Roberts RW, Crothers DM. Stability and properties of double and triple helices: Dramatic effects of RNA or DNA backbone composition. Science 258:1463-1466, 1992.
82. 82. Han H, Dervan PB. Sequence-specific recognition of double helical RNA and RNA · DNA by triple helix formation. Proc Natl Acad Sci USA 90:3806-3810, 1993.
83. 83. Escude C, Francois JC, Sun JS, Ott G, Sprinzl M, Garestier T, Helene C. Stability of triple helices containing RNA and DNA strands: Experimental and molecular modeling studies. Nucleic Acids Res 21:5547-5553, 1993.
84. 84. Pascolo E, Toulme JJ. Double hairpin complexes allow accommodation of all four base pairs in triple helices containing both DNA and RNA strands. J Biol Chem 271:24187-24192, 1996.
85. 85. Belikova AM, Grineva NI, Knorre DG, Mysina SD. Specific cleavage of DNA on guanosine residues by 2′.3′-O-[4-(N-2-chloroethyl-N-methylamino)benzylidine) uridine and its 5′-methyl-phosphate. Dokl Acad Natl SSSR 212:876-879, 1973.
86. 86. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280-284, 1978.
87. 87. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329-376, 1992.
88. 88. Leonetti JP, Degols G, Clarenc JP, Mechti N, Lebleu B. Cell delivery and mechanism of action of anti-sense oligonucleotides. Prog Nucleic Acid Res Mol Biol 44:143-166, 1993.
89. 89. Neckers L, Whitesell L, Rosolen A, Geselowitz DA. Anti-sense inhibition of oncogene expression. Crit Rev Oncogenesis 3:175-231, 1992.
90. 90. Jansen M, DeMoor CH, Sussenbach JS, Van Den Brande JL. Translational control of gene expression. Pediatr Res 37:681-686, 1995.
91. 91. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85:5011-5015, 1988.
92. 92. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261:1004-1012, 1993.
93. 93. Giles RV, Ruddell CJ, Spiller DG, Green JA, Tidd DM. Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res 23:954-961, 1995.
94. 94. Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci USA 92:8338-8342, 1995.
95. 95. Liu M, Liu J, Buch S, Tanswell AK, Post M. Antisense oligocucleotides for PDGF-B and its receptor inhibit mechanical strain-induced fetal lung cell growth. Am J Physiol 269:L178-184, 1995.
96. 96. Nakazono K, Ito Y, Wu CH, Wu GY. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 23:1297-1303, 1996.
97. 97. Pilowsky PM, Suzuki S, Minson JB. Antisense oligonucleotides: A new tool in neuroscience. Clin Exp Pharmacol Physiol 21:935-944, 1994.
98. 98. Sharma HW, Narayanan R. The therapeutic potential of antisense oligonucleotides. BioEssays 17:1055-1063, 1995.
99. 99. Scanlon KJ, Ohta Y, Ishida H, Kijima H, Ohkawa T, Kaminski A, Tsai J, Horng G, Kashani-Sabet M. Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 9:1288-1296, 1995.
100. 100. Wickstrom E, Bacon T, Wickstrom EL. Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res 52:6741-6745, 1992.
101. 101. Uhlmann E, Peyman A. Antisense oligonucleotides: A new therapeutic principle. Chem Rev 4:543-584, 1990.
102. 102. Aramini JM, Kalisch BW, Pon RT, van de Sande JH, Germann MW. Structure of a DNA duplex that contains alpha-anomeric nucleotides and 3′-3′ and 5′-5′ phosphodiester linkages: Coexistence of parallel and antiparallel DNA. Biochemistry 35:9355-9365, 1996.
103. 103. Stein CA, Mori K, Loke SL, Subasinghe C, Shinozuka K, Cohen JS, Neckers LM. Phosphorothioate and normal oligodeoxyribonucleotides with 5′-linked acridine: Characterization and preliminary kinetics of cellular uptake. Gene 72:333-341, 1988.
104. 104. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474-3478, 1989.
105. 105. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86:6454-6458, 1989.
106. 106. Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res 19:5543-5550, 1991.
107. 107. Budker VG, Knorre DG, Vlassov VV. Cell membranes as barriers for antisense constructions. Antisense Res Dev 2:177-184, 1992.
108. 108. Bonfils E, Depierreux C, Midoux P, Thuong NT, Monsigny M, Roche AC. Drug targeting: Synthesis and endocytosis of oligonucleotide-neoglyco-protein conjugates. Nucleic Acids Res 20:4621-4629, 1992.
109. 109. Barry ELR, Gesek FA, Friedman PA. Introduction of antisense oligonucleotides into cells by permeabilization with streptolysin O. BioFeedback 15:1018-1020, 1993.
110. 110. Burger DR. Novel antisense technology: Therapeutic and diagnostic applications. J Clin Immunol 16:224-230, 1993.
111. 111. Iversen PL, Zhu S, Meyer A, Zon G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 2:211-222, 1992.
112. 112. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270:2620-2627, 1995.
113. 113. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261:1004-1012, 1993.
114. 114. Citro G, Perrotti D, Cucco C, D'Adnano I, Sacchi A, Zupi G, Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89:7031-7035, 1992.
115. 115. Svinarchuk FP, Lavrovsky Y, Konevets DA, Vlasov VV. [Nuclear peptides, specifically binding oligonucleotides]. Mol Biol 27:305-308, 1993.
116. 116. Bielinska A, Kukowska-Latallo JF, Johnson J, Tomalia DA, Baker JR. Regulation of in vitro gene expression using antisense oligonucleotides of antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 24:2176-2182, 1996.
117. 117. Albrecht T, Schwab R, Peschel C, Engels HJ, Fischer T, Huber C, Aulitzky WE. Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modulation of gene expression. Ann Hematol 72:73-79, 1996.
118. 118. Altman S. Ribonuclease P: An enzyme with a catalytic RNA subunit. Adv Enzymol 62:1-36, 1989.
119. 119. Cech TR. Self-splicing and enzymatic activity of an intervening sequence RNA from Tetrohymena. New Chem Int Engl 29:759-768, 1989.
120. 120. Symons RH. Small catalytic RNAs. Annu Rev Biochem 61:641-671, 1992.
121. 121. Bratty J, Chartrand P, Ferbeyre G, Cedergren R. The hammerhead RNA domain, a model ribozyme. Biochim Biophys Acta 1216:345-359, 1993.
122. 122. Gesteland RF, Alkins JF. The RNA World, Monograph 24, Cold Spring Harbor Laboratory Press, Plainview, NY, 1993.
123. 123. Zaug AJ, Been MD, Cech TR. The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature 324:429-433, 1986.
124. 124. Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S. The RNA moiety of ribonuclease P is the catalytic sub-unit of the enzyme. Cell 35:849-857, 1983.
125. 125. Wu HN, Lin YJ, Lin FP, Makino S, Chang MF, Lai MM. Human hepatitis delta virus RNA subfragments contain an autocleavage activity. Proc Natl Acad Sci USA 86:1831-1835, 1989.
126. 126. Forster AC, Symons RH. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 49:211-220, 1987.
127. 127. Feldstein PA, Buzayan JM, Bruening G. Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA. Gene 82:53-61, 1989.
128. 128. Haseloff J, Gerlach WL. Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus. Gene 82:43-52, 1989.
129. 129. Perreault JP, Labuda D, Usman N, Yang JH, Cedergren R. Relationship between 2′-hydroxyls and magnesium binding in the hammerhead RNA domain: A model for ribozyme catalysis. Biochemistry 30:4020-4025, 1991.
130. 130. Uhlenbeck OC. A small catalytic oligonucleotide. Nature 328:596-600, 1987.
131. 131. Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 29:10695-10702, 1990.
132. 132. Thompson JD, Macejak D, Couture L, Seinchcomb DT. Ribozyme in gene therapy. Nature Med 1:277-278, 1996.
133. 133. Hampel A, Tritz R. RNA catalytic properties of the minimum (-) s TRSV sequence. Biochemistry 28:4929-4933, 1989.
134. 134. Fedor MJ, Uhlenbeck OC. Substrate sequence effect on "hammerhead" RNA catalytic efficiency. Proc Natl Acad Sci USA 87:1668-1672, 1990.
135. 135. Long DM, Uhlenbeck OC. Self-cleaving catalytic RNA. FASEB J 7:25-30, 1993.
136. 136. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: More isn't always better. Proc Natl Acad Sci USA 88:6921-6925, 1991.
137. 137. Bertrand E, Pictet R, Grange T. Can hammerhead ribozymes be efficient tools to inactivate gene function? Nucleic Acids Res 22:293-300, 1994.
138. 138. Pyle AM. Ribozymes: A distinct class of metalloenzymes. Science 261:709-714, 1993.
139. 139. Inokuchi Y, Yuyama N, Hirashima A, Nishikawa SAU, Ohkawa J, Taira K. A hammerhead ribozyme inhibits the proliferation of an RNA coliphage SP in Escherichia coli. J Biol Chem 269:11361-11366, 1994.
140. 140. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222-1225, 1990.
141. 141. Sioud M, Drlica K. Prevention of human immunodeficiency virus type I integrase expression in Escherichia coli by a ribozyme. Proc Natl Acad Sci USA 88:7303-7707, 1991.
142. + lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 65:5531-5534, 1991.
143. 143. Zaia JA, Chatterjee S, Wong KK, Elkins D, Taylor NR, Rossi JJ. Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy. Ann NY Acad Sci 660:95-106, 1992.
144. 144. Heidenreich V, Eckstein F. Hammerlead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type I. J Biol Chem 267:1904-1909, 1992.
145. 145. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 89:10802-10806, 1992.
146. 146. Chen CJ, Banerjea AC, Haglund K, Harmison GG, Schubert M. Inhibition of HIV-1 replication by novel multitarget ribozymes. Ann NY Acad Sci 660:271-273, 1992.
147. 147. Ho SP, Britton DH. Catalytic RNA molecules and their cleavage of viral mRNA. Ann NY Acad Sci 660:265-267, 1992.
148. 148. Homann M, Tzortzakaki S, Rittner K, Sczakiel G, Tabler M. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Res 21:2809-2814, 1993.
149. 149. Joseph S, Burke JM. Optimization of an anti-HIV hairpin ribozyme by in vitro selection. J Biol Chem 268:24515-24518, 1993.
150. 150. Sullenger BA, Cech TR. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262:1566-1569, 1993.
151. 151. Yu M, Ojwang J, Yamada O, Hampel A, Rapapport J, Looney D, Wong-Staal F. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90:6340-6344, 1993.
152. 152. Tang XB, Hobom G, Luo D. Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J Med Virol 42:385-395, 1994.
153. 153. Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, Kashani-Sabet M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88:10591-10595, 1991.
154. 154. Lange W, Cantin EM, Finke J, Dolken G. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ ABL mRNA. Leukemia 7:1786-1794, 1993.
155. 155. Ha J, Kim KH. Inhibition of fatty acid synthesis by expression of an acetyl-CoA carboxylase-specific ribozyme gene. Proc Natl Acad Sci USA 91:9951-9955, 1994.
156. 156. Kobayashi H, Dorai T, Holland JF, Ohnuman T. Reversal of drug sensitivity of multidrug-resistant tumor cells by an MDR1(RGY1) ribozyme. Cancer Res 54:1271-1275, 1994.
157. 157. Ferbeyre G, Bratty J, Chen H, Cedergren R. Cell cycle arrest promotes trans-hammerhead ribozyme action in yeast. J Biol Chem 271:19318-19323, 1996.
158. 158. Jarvis TC, Wincott FE, Alby LT, et al. Optimizing the cell efficiency of synthetic ribozyme. J Biol Chem 268:24515-24518, 1996.
159. 159. Ohkawa J, Koguma T, Kohda T, Taira K. Ribozymes: From mechanistic studies to applications in vivo. J Biochem 118:251-258, 1995.
160. 160. Kashani-Sabet M, Funato-Tone T, Jiao L, Wang W, Yoshida E, Kashfinn BI, Shitara T, Wu AM, Moreno JG, et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev 2:3-15, 1992.
161. 161. Eastham JA, Ahlering TE. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line. J Urol 156:1186-1188, 1996.
162. 162. Efrat S, Leiser M, Wu YJ, Fusco-DeMane D, Emran OA, Surana M, Jetton TL, Magnuson MA, Weir G, Fleischer N. Ribozyme-mediated attenuation of pancreatic beta-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion. Proc Natl Acad Sci USA 91:2051-2055, 1994.
163. 163. Larsson S, Hotchkiss G, Andang M, Nyholm T, Inzunza J, Jansson I, Ahrlund-Richter L. Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res 22:2242-2248, 1994.
164. 164. L'Huillier PJ, Soulier S, Stinnakre MG, Lepourry L, Davis SR, Mercier JC, Vilotte JL. Efficient and specific ribozymemediated reduction of bovine alpha-lactoalbumin expression in double transgenic mice. Proc Natl Acad Sci USA 93:6698-6703, 1996.
165. 165. Gotten M. The in vivo application of ribozymes. Trends Biotechnol 8:174-178, 1990.
166. 166. Rossi JJ, Sarver N. RNA enzymes (ribozymes) as antiviral therapeutic agents. Trends Biotechnol 8:179-183, 1990.
167. 167. Sanfacon H, Hohn T. Proximity to the promoter inhibits recognition of cauliflower mosaic virus polyadenylation signal. Nature 346:81-84, 1990.
168. 168. Chowrira BM, Pavco PA, McSwiggen JA. In vitro and in vivo comparison of hammerhead, hairpin, and hepatitis delta virus self-processing ribozyme cassettes. J Biol Chem 269:25856-25864, 1994.
169. 169. Cameron FH, Jennings PA. Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci USA 86:9139-9143, 1989.
170. 170. Zhao JJ, Pick L. Generating loss-of-function phenotypes of the fushi tarazu gene with a targeted ribozyme in Drosophila. Nature 365:448-451, 1993.
171. 171. Perriman R, Bruening G, Bennis ES, Peacock WJ. Effective ribozyme delivery in plant cells. Proc Natl Acad Sci USA 93:7219-7224, 1996.
172. 172. Michienzi A, Prislei S, Bozzoni I. U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. Proc Natl Acad Sci USA 93:7219-7224, 1996.
173. 173. Gotten M, Birnstiel M. Ribozyme mediated destruction of RNA in vivo. EMBO J 8:3861-3866, 1989.